Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom - Barron's
1. Trump's tariff policy threatens the pharmaceutical sector's stability. 2. Analysts predict tariffs could reduce sector earnings by 15%. 3. Eli Lilly is favored for its strong market position in obesity drugs. 4. Recent trial results for Orforglipron boost LLY's market potential. 5. Large-cap pharma stocks have dropped amid rising tariff concerns.